Anondita Medicare Ltd
Anondita Medicare Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
What the Q4 FY26 call signalled
4 of 4 strong
The short version
Company expects major revenue growth driven by increased capacities and international market expansion. Revenue is expected to reach INR1,000 crores within the next 2 years, implying around 100% year-on-year growth.
From Anondita Medicare Ltd's Q4 FY26 earnings-call transcript · updated 26 Sept 2026.
Revenue & Sales Performance
- Company expects major revenue growth driven by increased capacities and international market expansion.
- Total manufacturing capacity increased from 562 million to 806 million condoms annually, with initial utilization expected around 75%.
- Anticipates doubling revenue to INR 1,000 crores within the next 2 years.
- Expects 25% capacity addition to contribute INR 325 crores turnover in the coming year.
- Focus on export markets including South Africa (1 billion pieces tender over 5 years), Brazil, and others, to drive volume growth.
- Plans to launch innovative products (spiral condoms, non-latex male condoms, female condoms) to capture market share.
- Government business expected to grow moderately (~5-10%), but primary focus on own brand "Cobra" and exports with higher margins.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anondita Medicare Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company undertook significant capex in FY 2026, adding to property, plant, and equipment, with CWIP also increased.
- Total capex done last year was approximately INR 62 crores; out of that, INR 24 crores was already spent, expanding capacity to 307 million units.
- Additional capacity under WIP is expected to increase capacity by 250 million units, aiming for a turnover of around INR 325 crores from this expansion.
- The capex was completed by end of December, so depreciation expense impact in FY 2026 was limited to one quarter.
- The company has patented in-house manufacturing machines, which facilitate faster and lower-cost capacity expansion compared to competitors.
2 more points management made on capital expenditure plans
Top-ranked in Personal Products
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anondita Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year.
- The company has secured a single rate contract as the sole L1 supplier to the Government of India National AIDS Control Society, ensuring continuous government orders.
- Registered in South Africa for the next five years with a requirement of 1 billion pieces annually; expects to execute about 25% of that order this year, leading to significant revenue jump.
- Order pipeline includes international orders from countries like Kenya, Uzbekistan, Brazil, and South Africa under their own brand "Cobra."
2 more points management made on order book & pipeline
Continue your research
Others in Personal Products this season
- Cupid Ltd (Q4 FY26)
Q4 FY26 Revenue from operations: ₹119.96 Cr, up 112.39% YoY from ₹56.48 Cr in Q4 FY25 (Page 18). Key investor presentation takeaways from Cupid Ltd's Q4 FY26 in
- Honasa Consumer (Q4 FY26)
Increasing contribution from focus categories, which grew 35% year-on-year and now receive over 90% of investments. Key concall takeaways from Honasa Consumer…
- Bajaj Consumer Care Ltd (Q4 FY26)
Revenue growth momentum is strong, with a 21% increase for the full year FY26 and a 30% top-line growth noted in Q4. Key concall takeaways from Bajaj Consumer…
- Godrej Consumer (Q4 FY26)
Operating metrics such as ARR for Fab portfolio (~INR 500 crores GSV). Key concall takeaways from Godrej Consumer's Q4 FY26 earnings call — and how it ranks…
Frequently Asked Questions
What were Anondita Medicare Ltd Q4 FY26 results?
Company expects major revenue growth driven by increased capacities and international market expansion. Revenue is expected to reach INR1,000 crores within the next 2 years, implying around 100% year-on-year growth.
What is Anondita Medicare Ltd share price analysis?
Anondita Medicare Ltd currently shows a strong growth signal based on ranking data. The stock trades at a P/E of 62.1 with a market cap of ₹2,077 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anondita Medicare Ltd planning capital expenditure?
The company undertook significant capex in FY 2026, adding to property, plant, and equipment, with CWIP also increased.
Keep Anondita Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.